Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 43 44 45 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Scil–Coral BioNet: investment, 201102 financing round €24m for Scil Proteins from own majority holder BioNet Holding 2011-02-02
SuperGen–Proteros: drug discovery services, 201102– supply service use integrated lead discovery platform to discover small-molecule lead compounds 2011-02-02
Genzyme–Sekisui: investment, 201102 acquisition of Genzyme Virotech GmbH by Sekisui Chemial 2011-02-01
PharmaSwiss–Valeant: investment, 201102–201103 acquisition €350m + €30m milestones 2011-02-01
SAW Instruments–Germany (govt): investment, 201102 2nd financing round totalling €1m incl new investor KfW 2011-02-01
SAW Instruments–High-Tech Gründerfonds: investment, 201102 2nd financing round totalling €1m incl returning investor High-Tech Gründerfonds 2011-02-01
SAW Instruments–KI Kapital: investment, 201102 2nd financing round totalling €1m incl returning investor KI Kapital GmbH 2011-02-01
SAW Instruments–SEVERAL: investment, 201102 2nd financing round €1m KI Kapital + HTGF + KfW 2011-02-01
Resource Technology Corp–Sigma-Aldrich: investment, 201101 acquisition of assets of RTC €na by Sigma-Aldrich 2011-01-31
Bayer–Zydus Cadila: pharmaceuticals, 201101– collab 50/50 joint venture Bayer Zydus Pharma established to develop Indian market 2011-01-28
FCB-Pharmicell–RNL Bio: investment, 201101 acquisition 99.5% of Pharmicell Europe GmbH to be renamed RNL Europe GmbH 2011-01-25
Genoptix–Novartis: investment, 201101– cash tender offer $470m $25/share 2011-01-24
Genoptix–Novartis: investment, 201701–201703 DIVESTMENT sale €na of Genoptix (excl biopharma business) to Ampersand + 1315 Capital + new managers 2011-01-24
Takeda–Evotec: drug discovery services, 201101– supply service €na identification small molecules against CNS + metabolic targets for Takeda Cambridge 2011-01-20
Merck (DE)–Domain Therapeutics: mGLuR4 PAM, 201101– collab excl developm + licensing €2m upfront + €132m milestones + royalties for Parkinson 2011-01-17
Mologen–Salvator Vermögensverwaltungs GmbH: investment, 201101 existent long-time investor 2011-01-14
Univ Bonn–Bruker Corp: mass spectrometer, 201101 supply existent HCT Ultra at IBMB 2011-01-14
Univ Bonn–Bruker Corp: mass spectrometer, 201101 supply existent HCT Ultra ETD at IBMB 2011-01-14
Univ Bonn–Danaher: mass spectrometer, 201101 supply existent ABI STR Voyager at IBMB 2011-01-14
Univ Bonn–Thermo Fisher: mass spectrometer, 201101 supply existent LTQ Orbitrap Velos at IBMB 2011-01-14
4-Antibody–Advent Venture Partners: investment, 201101 existent listed as current portfolio company of Advent 2011-01-13
Caterna–High-Tech Gründerfonds: investment, 201101 financing round totalling €650k incl investor High-Tech Gründerfonds 2011-01-13
Caterna–Saxony (govt): investment, 201101 financing round totalling €650k incl investor Technologiegründerfonds Sachsen 2011-01-13
Caterna–SEVERAL: investment, 201101 financing round €650k from Technologiegründerfonds Sachsen + High-Tech Gründerfonds 2011-01-13
Laboratoires Expanscience–Medigene: Veregen, 201001– license + supply for excl commercialisation + marketing in France 2011-01-13
Medigene–Advent Venture Partners: investment, 201101 existent listed as current portfolio company of Advent 2011-01-13
Micromet–Advent Venture Partners: investment, 201101 existent listed as current portfolio company of Advent 2011-01-13
Mologen–Berliner Effektengesellschaft: financial services, 201101 service Quirin Bank subscription agent for capital increase up to 1.246m new shares 2011-01-13
Mologen–Kirchhoff Consult: public relations, 201101 service existent investor relations 2011-01-13
Mologen–SEVERAL: investment, 201101–201102 capital increase €10m 1.246m new shares €8/share 2011-01-13
DiaSorin–Tecan: lab automation, 201101– supply €na OEM automated ELISA system based on Freedom EVOlyzer platform incl detetcion instruments 2011-01-12
EyeSense–Qiagen: investment, 201101 acquisition minority equity stake €na by Qiagen in connection with strategic partnership 2011-01-12
Qiagen–EyeSense: blood glucose measuring device, 201101– collab development combining EyeSene techn with ESE fluorescence-based optical techn 2011-01-12
Vaximm–SEVERAL: investment, 201101 financing round private CHF7.8m 2011-01-12
Alacris–Max Planck: ModCell™ system, 201101 license excl existent from MPI for Molecular Genetics 2011-01-11
Alacris–Qiagen: investment, 201101 acquisition €na minority stake 2011-01-11
Alcon–MerLion: finafloxacin, 201101– license excl developm + commercialisation in North America for ear infections w option to expand license 2011-01-11
Bayer–Univ California: pharma research, 201101– master agreement for research collaborations of Bayer HealthCare with UCSF 2011-01-11
Lilly–Boehringer: antidiabetic drugs, 201101– collab strategic alliance ww joint developm + marketing of portfolio of diabetes drugs 2011-01-11
LZS-Concept–Analytik Jena: laboratory equipment, 201101– distribution and service in Austria by LZS-Concept Handels- und Service GmbH 2011-01-11
Qiagen–Alacris: biomarker, 201101– excl option €na to access all biomarkers for individualised cancer treatment 2011-01-11
Roche–Expression Pathology: Liquid Tissue-SRM technology, 201101– supply protein biomarker assay services to support Roche oncology drug development 2011-01-11
Tecan–Enigma Diagnostics: molecular diagnostics, 201101– license + collab €na use of Enigma ML for OEM diagnostic platforms by Tecan 2011-01-11
AJ Innuscreen–Analytik Jena: investment, 201101 investment increase of ownership to 100% 2011-01-10
Apeiron–PR&D: public relations, 201101 service strategic communication consulting + national + international media service 2011-01-10
Comicom–Analytik Jena: investment, 201101 acquisition 55% by AJ Blomesystem GmbH 2011-01-10
Gilupi–Aurelia Private Equity: investment, 201101 3rd financing round totalling €3.6m incl investor Aurelia Private Equity 2011-01-10
Gilupi–Brandenburg (govt): investment, 201101 3rd financing round totalling €3.6m incl investor Brandenburg Capital BFBII 2011-01-10
Gilupi–Germany (govt): investment, 201101 3rd financing round totalling €3.6m incl investor KfW Bankengruppe 2011-01-10
Gilupi–High-Tech Gründerfonds: investment, 201101 3rd financing round totalling €3.6m incl investor HTGF 2011-01-10
Gilupi–SEVERAL: investment, 201101 3rd financing round €3.6m Aurelia Private Equity + Brandenburg Capital + KfW+ High-Tech Gründerfonds 2011-01-10
JnJ–Biocartis: molecular diagnostics, 201101– strategic collab €na ww excl co-developm + marketing assays for neurological disease + some infections 2011-01-10
Synosia–Biotie: investment, 201101–201102 merger acquisition €93.6m 2011-01-10
Takeda–Pieris: Anticalin scaffold technology, 201101– collab €na drug discovery Anticalin therapeutic protein candidates Takeda San Francisco 2011-01-10
Teva–Lonza: biogenerics, –201101–201307 collab joint venture TERMINATED 7/13 2011-01-10
AstraZeneca–Kinaxo: mass spectrometry services, 201101– supply service €na Kinaxo to apply its technology to support one AZ oncology program 2011-01-05
Lonza–IDBS: data management software, 201101– supply Bioprocess Execution System software for mammalian cell culture process development 2011-01-05
sense2care–High-Tech Gründerfonds: investment, 201101 HTGF invests €500k 2011-01-04
Centogene–PERSON: investment, 201101 equity investment Martin Schlenk becomes major shareholder + CEO of Centogene Holding AG 2011-01-01
Dr. Falk Pharma–Zedira: transglutaminase inhibitor, 2011– license to ZED1227 in Europe plus joint ownership of rights outside Europe 2011-01-01
iThera Medical–Germany (govt): grant, 2011 GO-Bio phase 2 grant from BMBF 2011-01-01
JnJ–Molecular Partners: DARPins, 2011–201610 collab + license DARPin targeting IL-13 + IL-17 against pulmonary disease TERMINATED 10/16 2011-01-01
MicroAQUA project–EU (govt): grant, 2011– FP7 grant to develop DNA microarray for water analysis 2011-01-01
MicroAQUA project–Scienion: DNA microarrays, 2011– collab Scienion is project member + final marketer of resulting DNA microarray for water analysis 2011-01-01
Pfizer–Kohlberg Kravis Roberts: investment, 2011 acquisition of Capsugel from Pfizer by KKR 2011-01-01
Select Biosciences–Alto Marketing: public relations, 2011– service public relations for European Lab Automation in Hamburg 2011 + 2012 2011-01-01
Springer–ASMS: Journal of the American Society for Mass Spectrometry, 2011– collab Springer to publish ASMS Journal before Elsevier 2011-01-01
Univ Bremen–Bruker Corp: mass spectrometer, 2011 supply autoflex speed LRF MALDI-TOF MS to new MALDI Imaging Lab 2011-01-01
Univ Cambridge–Agilent: mass spectrometer, 2011 supply Agilent 6460 Triple Quad MS with 1290 Infinity LC to Ralser Lab 2011-01-01
Univ Heidelberg–Bruker Corp: mass spectrometer, 2011c supply use of MALDI Biotyper at Univ Hospital Heidelberg 2011-01-01
Vita Diagnostika–Euro Diagnostica: investment, 2011 acquisition 2011-01-01
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies 2011-01-01
Cytonet–SEVERAL: investment, 201012 financing round €5.4m 2010-12-31
Hyglos–SEVERAL: investment, 201012 financing round €4.5m 2010-12-31
Cerilliant–Sigma-Aldrich: investment, 201012 acquisition €na of all outstanding shares 2010-12-30
MMT GmbH–Plan Optik: investment, 201012 acquisition of 70% majority share by Plan Optik 2010-12-27
Jacobs Univ–Bruker Corp: mass spectrometer, 201012 supply existent autoflex II MALDI-TOF at lab of Prof Nikolai Kuhnert 2010-12-22
Jacobs Univ–Bruker Corp: mass spectrometer, 201012 supply existent HCT ultra ion trap at lab of Prof Nikolai Kuhnert 2010-12-22
Jacobs Univ–Bruker Corp: mass spectrometer, 201012 supply existent micro TOFQ ESI at lab of Prof Nikolai Kuhnert 2010-12-22
Cevec–SEVERAL: investment, 201012 financing round €4.3m 1st closing 2010-12-21
Sigma ElectroOptics–Bruker Corp: investment, 201012 acquisition €na 2010-12-21
TKA Wasseraufbereitungssysteme–Thermo Fisher: investment, 201012 acquisition 2010-12-21
Nanohale–SEVERAL: investment, 201012 IPO €4.35m at Frankfurt Stock Exchange 2010-12-20
Novimmune–SEVERAL: investment, 201012 financing round Series B CHF20m led by BZ Bank AG 2010-12-17
Wilex–Hopp Group: credit, 201012– subordinated loan up to €7.5m interest rate 6% annual from Dievini Hopp BioTech Holding GmbH & Co KG 2010-12-17
Wilex–UCB: credit, 201012–201405 subordinated loan up to €2.5m interest rate 6% annual from UCB Pharma SA REPAYMENT WAIVED 5/14 2010-12-17
AstraZeneca–Evotec: antidiabetics, 201012– collab + license agreement €5m upfront + up to €254m milestones + royalties Develogen + MedImmune 2010-12-15
Nestlé–Novartis: investment, 201012–21104 acquisition of remaing shares of Alcon 2010-12-15
Merck (DE)–San Raffaele: drug development, 201012– collab strategic clinical research drugs for neurodegenerative diseases incl MS with Merck Serono 2010-12-13
Merck (DE)–San Raffaele: drug development, 201407– collab extension pre- + clinical research drugs for neurodegenerative diseases Merck Serono 2010-12-13
SciEngines–Schleswig-Holstein (govt): grant, 201012 grant €230k for development of Field Programmable Gate Arrays for bioinformatics 2010-12-09
Zweckverband Landeswasserversorgung–Danaher: mass spectrometer, 201012– supply AB Sciex TripleTOF 5600 to Waterworks Langenau + collab method developm 2010-12-08
SuppreMol–Germany (govt): grant, 201012– BMBF grant €1.6m to expand indications for SM101 as part of m4 Cluster initiative 2010-12-06
APHP–Bruker Corp: mass spectrometer, 201012– supply MALDI Biotyper as excl MALDI-TOF solution 3 new orders + 2 already used for years 2010-12-02
Dynacare–Bruker Corp: mass spectrometer, 201012 supply purchase of MALDI Biotyper as 5th clinical lab in US + 1st lab in Wisconsin 2010-12-02
HolsboerMaschmeyer Neurochemie–PERSON: investment, 201012 founding with Carsten Maschmeyer owning 50% 2010-12-02
HolsboerMaschmeyer Neurochemie–PERSON: investment, 201012 founding with Florian Holsboer owning 50% 2010-12-02
LZS-Concept–Bruker Corp: mass spectrometer, 201012 distribution existent in Austria by LZS-Concept GmbH 2010-12-02
ImaGenes–Source BioScience: investment, 201012 acquisition £2m in cash 2010-12-01
SuppreMol–SEVERAL: investment, 201012 financing round Series C €15.5m led by MIG AG w co-lead investor BioMedPartners 2010-12-01
next pagenext page 1 2 3 ... 43 44 45 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top